Dispensing of anxiolytics and hypnotics in southeastern France: Demographic factors and determinants of geographic variations

Fundamental and Clinical Pharmacology

Volumn 22, Issue 3, 2008, Pages 323-333

  Bocquier, Aurélie ^a,b   Bezzou, Kamel ^a,b   Nauleau, Steve ^c   Verger, Pierre ^a,b  

^a OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^b INSERM   (France)

^c Southeastern Regional Federation of Health Insurance Funds   (France)

Author keywords

Anti anxiety agents; Hypnotics and sedatives; Psychotropic drugs; Small area analysis; Socioeconomic factors

Indexed keywords

ANXIOLYTIC AGENT; HYPNOTIC SEDATIVE AGENT; PSYCHOTROPIC AGENT;

ARTICLE; CALCULATION; CHRONIC DISEASE; DATA BASE; DEMOGRAPHY; DESCRIPTIVE RESEARCH; FRANCE; GENERAL PRACTITIONER; GEOGRAPHICAL VARIATION (SPECIES); HUMAN; INCOME; INSURANCE; MENTAL DISEASE; MULTIPLE LINEAR REGRESSION ANALYSIS; OUTPATIENT; PHARMACY; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SOCIOECONOMICS; UNEMPLOYMENT;

ADULT; AGE DISTRIBUTION; AGED; ANTI-ANXIETY AGENTS; DRUG UTILIZATION; FRANCE; HUMANS; HYPNOTICS AND SEDATIVES; MIDDLE AGED; POPULATION SURVEILLANCE; PRESCRIPTIONS, DRUG; SEX DISTRIBUTION; SOCIOECONOMIC FACTORS;

EID: 44049083067     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00587.x     Document Type: Article

References (73)

1. Alonso J., Angermeyer M.C., Bernert S. et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. Suppl. (2004) 420 55 64.
2. Ohayon M.M., Lader M.H. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J. Clin. Psychiatry (2002) 63 817 825.
3. Gasquet I., Negre-Pages L., Fourrier A. et al. Psychotropic drug use and mental psychiatric disorders in France; results of the general population ESEMeD/MHEDEA 2000 epidemiological study. Encephale (2005) 31 195 206.
4. Legrain M., Lecomte T. The consumption of psychotropics in France and some European countries. Ann. Pharm. Fr. (1998) 56 67 75.
5. Pelissolo A., Boyer P., Lepine J.P., Bisserbe J.C. Epidemiology of the use of anxiolytic and hypnotic drugs in France and in the world. Encephale (1996) 22 187 196.
6. Nutt D., Mendelson W. Bailliere's clinical psychiatry: hypnotics and anxiolytics, Bailliere Tindall, London, 1995.
7. Schweizer E., Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr. Scand. Suppl. (1998) 393 95 101.
8. Lagnaoui R., Begaud B., Moore N. et al. Benzodiazepine use and risk of dementia: a nested case-control study. J. Clin. Epidemiol. (2002) 55 314 318.
9. Blain H., Blain A., Trechot P., Jeandel C. The role of drugs in falls in the elderly. Epidemiologic aspects. Presse Med. (2000) 29 673 680.
10. Barbone F., McMahon A.D., Davey P.G. et al. Association of road-traffic accidents with benzodiazepine use. Lancet (1998) 352 1331 1336.
11. Leipzig R.M., Cumming R.G., Tinetti M.E. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J. Am. Geriatr. Soc. (1999) 47 30 39.
12. CNAMTS. Direction des études et des statistiques. Prescriptions médicales et disparités géographiques, CNAMTS, Paris, 2004.
13. Lecadet J., Vidal P., Baris B. et al. Médicaments psychotropes : consommation et pratiques de prescription en France métropolitaine. II. Données et comparaisons régionales, 2000. Rev. Med. Ass. (2003) 34 233 248.
14. Parchman M.L. Small area variation analysis: a tool for primary care research. Fam. Med. (1995) 27 272 276.
15. Paul-Shaheen P., Clark J.D., Williams D. Small area analysis: a review and analysis of the North American literature. J. Health Polit. Policy Law (1987) 12 741 809.
16. Anis A.H., Carruthers S.G., Carter A.O., Kierulf J. Variability in prescription drug utilization: issues for research. CMAJ (1996) 154 635 640.
17. King D.J., Griffiths K., Reilly P.M., Merrett J.D. Psychotropic drug use in Northern Ireland 1966-80: prescribing trends, inter- and intra-regional comparisons and relationship to demographic and socioeconomic variables. Psychol. Med. (1982) 12 819 833.
18. Curtis S., Copeland A., Fagg J., Congdon P., Almog M., Fitzpatrick J. The ecological relationship between deprivation, social isolation and rates of hospital admission for acute psychiatric care: a comparison of London and New York City. Health Place (2006) 12 19 37.
19. Almog M., Curtis S., Copeland A., Congdon P. Geographical variation in acute psychiatric admissions within New York City 1990-2000: growing inequalities in service use? Soc. Sci. Med. (2004) 59 361 376.
20. Cox E.R., Motheral B.R., Henderson R.R., Mager D. Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: results from a commercially insured US sample. Pediatrics (2003) 111 237 243.
21. Reid R., Hakendorf P., Prosser B. Use of psychostimulant medication for ADHD in South Australia. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41 906 913.
22. Curtis L.H., Stoddard J., Radeva J.I. et al. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States. Health Serv. Res. (2006) 1 837 855.
23. Prince M., Patel V., Saxena S. et al. No health without mental health. Lancet (2007) 370 859 877.
24. Lecadet J., Vidal P., Baris B. et al. Médicaments psychotropes : consommation et pratiques de prescription en France métropolitaine. I. Données nationales, 2000. Rev. Med. Ass. (2003) 34 75 84.
25. Mancini J., Thirion X., Masut A. et al. Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol. Drug Saf. (2006) 15 494 503.
26. CNAMTS. La population protégée par les régimes de sécurité sociale. Répartition géographique par département et par circonscription de caisse primaire au 31 décembre 2001, CNAMTS, Paris, 2003.
27. Diehr P., Cain K., Connell F., Volinn E. What is too much variation? The null hypothesis in small-area analysis. Health Serv. Res. (1990) 24 741 771.
28. Fender P., Paita M., Ganay D., Benech J.M. Prevalence of thirty long-term disorders for French health insurance members in 1994. Rev. Epidemiol. Sante Publique (1997) 45 454 464.
29. Fender P., Megnigbeto C. Morbidity estimates of beneficiaries of national health insurance for seven chronic conditions. Rev. Epidemiol. Sante Publique (1997) 45 193 202.
30. Vallier N., Salanave B., Weill A. Disparités géographiques de la santé en France : les affections de longue durée. Points de repère. (2006) 1 1 8.
31. Trifiro G., Spina E., Brignoli O., Sessa E., Caputi A.P., Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur. J. Clin. Pharmacol. (2005) 61 47 53.
32. Kaye J.A., Bradbury B.D., Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br. J. Clin. Pharmacol. (2003) 56 569 575.
33. Institut national de santé publique du Québec. Doit-on utiliser la standardisation directe ou indirecte dans l'analyse de la mortalité à l'échelle des petites unités géographiques?, Institut national de santé publique du Québec, Québec, 2005.
34. Kennedy S., Lam R., Morris B. (2007) Clinical guidelines for depressive disorders. Summary of recommendations relevant to family physicians [WWW document]. URL http://www.cfpc.ca/cfp/2003/Apr/vol49-apr-resources-2.asp (last accessed on 16 April 2008).
35. Uhlenhuth E.H., Balter M.B., Ban T.A., Yang K. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress Anxiety (1999) 9 107 116.
36. Verger P., Saliba B., Rouillon F. et al. Determinants of co-prescription of anxiolytics with antidepressants in general practice. Can. J. Psychiatry (2008) 53 94 103.
37. Haute Autorité de Santé. Société de formation thérapeutique du généraliste, Haute Autorité de Santé. Prise en charge du patient adulte se plaignant d'insomnie en médecine générale, HAS, Saint-Denis La Plaine, 2006.
38. Haute Autorité de Santé. Modalités d'arrêt des benzodiazépines et médicaments apparentés chez le patient âgé, HAS, Saint-Denis La Plaine, 2007.
39. van Weel-Baumgarten E.M., van Rijswijk E. The practice guideline 'Anxiety disorders' (first revision) from the Dutch College of General Practitioners; a response from the perspective of general practice. Ned. Tijdschr. Geneeskd. (2005) 149 1197 1199.
40. Practice guidelines - therapy of anxiety and compulsive disorders. Recommendations for therapy of anxiety and compulsive disorders of the Drug Commission of the German Medical Society. Z Arztl Fortbild Qualitatssich. (2000) 94 241 244.
41. National Health Service, National Institute for Clinical Excellence. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia, NHS, London, 2004.
42. Recommendations for drug therapy in anxiety. Serotoninergic agents to replace benzodiazepines. Drug Administration Office (Sweden) and State Drug Control(Norway). Lakartidningen. (1995) 92 1256 1261.
43. Office parlementaire d'évaluation des politiques de santé. Rapport sur le bon usage des médicaments psychotropes, par Mme Maryvonne BRIOT, Députée, 2006.
44. Morabia A., Fabre J., Dunand J.P. The influence of patient and physician gender on prescription of psychotropic drugs. J. Clin. Epidemiol. (1992) 45 111 116.
45. Alonso J., Angermeyer M.C., Bernert S. et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr. Scand. (2004) 420 21 27.
46. Ashton H. Psychotropic-drug prescribing for women. Br. J. Psychiatry Suppl. (1991) May 30 35.
47. Tamblyn R., Laprise R., Schnarch B., Monette J., Mc Leod P. Caractéristiques des médecins prescrivant des psychotropes davantage aux femmes qu'aux hommes, in : Cohen D., Pérodeau G. (Eds Drogues et médicaments mis en contexte, Santé Mentale au Québec, Québec, 1996, pp. 183 199.
48. Baumann M., Pommier J., Deschamps J.P. Medical prescription and consumption of psychotropic drugs: questions on the differences between men and women. Cah. Sociol. Demogr. Med. (1996) 36 63 78.
49. Glass J., Lanctot K.L., Herrmann N., Sproule B.A., Busto U.E. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ (2005) 331 1169.
50. Bokhari F., Mayes R., Scheffler R.M. An analysis of the significant variation in psychostimulant use across the U.S. Pharmacoepidemiol. Drug Saf. (2005) 14 267 275.
51. Roberts E., Norris P. Regional variation in anti-depressant dispensings in New Zealand: 1993-1997. N. Z. Med. J. (2001) 114 27 30.
52. Brunot A., Lachaux B., Sontag H. et al. Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale (2002) 28 129 138.
53. Clark R.E., Bartels S.J., Mellman T.A., Peacock W.J. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr. Bull. (2002) 28 75 84.
54. Boyer P., Dardennes R., Even C., Gaillac V., Gérard A., Lecrubier Y. et al. Dépression et santé publique: données et réflexions, Acanthe, Masson ed, Paris, 1999.
55. Stunkard A.J., Faith M.S., Allison K.C. Depression and obesity. Biol. Psychiatry (2003) 54 330 337.
56. Ohayon M. Epidemiological study on insomnia in the general population. Sleep (1996) 19 (Suppl. 3) S7 S15.
57. Magrini N., Vaccheri A., Parma E. et al. Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. Eur. J. Clin. Pharmacol. (1996) 50 19 25.
58. Paulose-Ram R., Jonas B.S., Orwig D., Safran M.A. Prescription psychotropic medication use among the U.S. adult population: results from the third National Health and Nutrition Examination Survey, 1988-1994. J. Clin. Epidemiol. (2004) 57 309 317.
59. Neutel C.I. The epidemiology of long-term benzodiazepine use. Int. Rev. Psychiatry (2005) 17 189 197.
60. Arwidson P., Guilbert P. Consommation de soins et de médicaments, in : Guilbert P., Baudier F., Gautier A. (Eds Baromètre santé 2000 Résultats Volume 2, éditions CFES, Vanves, 2001, pp. 311 324.
61. Fone D., Dunstan F., Lloyd K., Williams G., Watkins J., Palmer S. Does social cohesion modify the association between area income deprivation and mental health? A multilevel analysis. Int. J. Epidemiol. (2007) 36 338 345.
62. Diez-Roux A.V., Nieto F.J., Muntaner C. et al. Neighborhood environments and coronary heart disease: a multilevel analysis. Am. J. Epidemiol. (1997) 146 48 63.
63. Driant J. Les ménages à bas revenus et le logement social. Insee Première. (2004) 962 1 4.
64. Trugeon A., Fontaine D., Lémery B. Inégalités socio-sanitaires en France. De la région au canton. Abrégé s, Elsevier Masson S.A.S., Paris, 2006.
65. Andersson S.J., Lindberg G., Troein M. General practitioners' conceptions of depressive disorders in relation to regional sales levels of antidepressive drugs. A study based on a postal survey and ecological data. Scand. J. Prim. Health Care (2005) 23 11 17.
66. Chassin M.R. Explaining geographic variations. The enthusiasm hypothesis. Med. Care (1993) 31 (Suppl. 5) YS37 YS44.
67. Zandstra S.M., Furer J.W., van de Lisdonk E.H., Bor J.H., Zitman F.G., van Weel C. Differences in health status between long-term and short-term benzodiazepine users. Br. J. Gen. Pract. (2002) 52 805 808.
68. Fourrier A., Letenneur L., Dartigues J.F., Moore N., Begaud B. Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use. Eur. J. Clin. Pharmacol. (2001) 57 419 425.
69. Barnas C., Whitworth A.B., Fleischhacker W.W. Are patterns of benzodiazepine use predictable? A follow-up study of benzodiazepine users. Psychopharmacology (Berl.) (1993) 111 301 305.
70. Verger P., Aulagnier M., Protopopescu C. et al. Hypnotic and tranquillizer use among general practitioners in south-eastern France and its relation to occupational characteristics and prescribing habits. Fundam. Clin. Pharmacol. (2004) 18 379 385.
71. Villani P., Morciano C., Ambrosi P. et al. Prescriptions and consumption of hypnotic and anxiolytic drugs in the South University Hospital of Marseille. Therapie (2001) 56 11 14.
72. DRTEFP PACA. Les chiffres clés du travail, de l'emploi et de la formation professionnelle - Année 2005, DRTEFP PACA, Marseille, 2005.
73. DRTEFP PACA. Les chiffres clés du travail, de l'emploi et de la formation professionnelle - Année 2000, DRTEFP PACA, Marseille, 2000.